pSivida (PSDV) Rips Again; Traders Eye Further European Approval for ILLUVIEN (ALIM)
Tweet Send to a Friend
Up)
pSivida (Nasdaq: PSDV) is ripping higher again Tuesday following a 13.7 percent move Monday.
Investors and traders are gearing up as Alimera Sciences' (Nasdaq: ALIM) ILLUVIEN is expected to be approved in about seven European countries by the end of the quarter. pSivida is slated to receive royalties on ILLUVIEN, about 20 percent of net profits which will be determined on a country-by-country basis. Further, if Alimera decides to partner-up for European commercialization, pSivida will get 33 percent of any lump sum received plus an additional 20 percent of Alimera's net profits.
Shares are 14.8 percent better Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Investors and traders are gearing up as Alimera Sciences' (Nasdaq: ALIM) ILLUVIEN is expected to be approved in about seven European countries by the end of the quarter. pSivida is slated to receive royalties on ILLUVIEN, about 20 percent of net profits which will be determined on a country-by-country basis. Further, if Alimera decides to partner-up for European commercialization, pSivida will get 33 percent of any lump sum received plus an additional 20 percent of Alimera's net profits.
Shares are 14.8 percent better Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Clearwire (CLWR) Active as DISH Eyes Lightsquared Spectrum
- Apple (AAPL) Continues Higher
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
